Premature

Virginia Milk Bank Seeks Donors for Hospitalized Babies

Retrieved on: 
Wednesday, March 20, 2024
Breast milk, Jaundice, Retinopathy, Nutrient, Lactation, Disease, Memory, Short bowel syndrome, CHKD, Risk, Necrotizing enterocolitis, Hospital, Milk, American Academy, Infant, Death, NICU, Life, Protein, Kidney disease, Intraparenchymal hemorrhage, Woman, Holiday, Antibody, Oxygen, Premature, Paratriathlon, Charli, ROP, Pediatrics (journal), Pediatrics, Dairy

Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.

Key Points: 
  • Knowing that her breast milk was the best nutrition for Charli, Moultrie tried pumping to get her milk supply started.
  • After two weeks of consistently pumping with scant results, Moultrie was grateful to learn that Charli could receive safe, pasteurized human milk through the hospital's donor milk bank.
  • The milk bank also has a legacy program for women who have lost a baby but want to donate their milk to help other infants.
  • “But there are times around the holidays and during the summer when we only have enough milk for hospitalized babies.”
    This means the milk bank is not always able to provide milk to babies who have been discharged from the hospital with a doctor’s prescription for pasteurized donor human milk.

Researchers at Phoenix Children's First in the World to Produce Mouse Lungs in Rats

Retrieved on: 
Monday, March 25, 2024
Research, ESC, Bioreactor, B cell, Regeneration, Neurology, Rat, Cell, Osteogenesis imperfecta, Assistant, Cardiology, Critical Care Medicine (journal), Patient, American Journal, DNA, Pharmacist, Manuscript, Cancer, University, Hope, Doctor of Philosophy, Lung transplantation, MD, Biostatistics, Respiratory failure, Cas9, CRISPR, Stem cell, Premature, Research institute, College of Engineering (KNUST), Medicine, Nursing, Animal

PHOENIX, March 25, 2024 /PRNewswire/ -- Research conducted at the Phoenix Children's Research Institute at the University of Arizona College of Medicine — Phoenix reports the successful generation of a mouse lung in a rat, according to a paper published in the American Journal of Respiratory and Critical Care Medicine.

Key Points: 
  • The critical differentiating factor with this study is researchers incorporated CRISPR-Cas9, a unique genome editing technology that allows researchers to change genomes by altering sections of the DNA sequence.
  • Modifications of rat embryos by CRISPR-Cas9 allowed the formation of lung tissues consisting of almost all mouse lung cells.
  • This is one of many recent accolades for the Phoenix Children's Research Institute.
  • The Phoenix Children's Research Institute at the University of Arizona College of Medicine –Phoenix launched in May 2023, formalizing a longstanding research collaboration between the health system and the University of Arizona College of Medicine – Phoenix.

QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada

Retrieved on: 
Wednesday, March 6, 2024
Data Management, Biotechnology, Baby, Maternity, Technology, Other Health, Health, Women, Health Technology, Medical Devices, Consumer, Clinical Trials, Pre-eclampsia, Eclampsia, Woman, Transfusion medicine, QuidelOrtho, Health Canada, Quality, Premature, Pregnancy, Risk, Diagnosis, Quality control, Safety, Prognosis, Biomarker, Lancet, Triage, Stillbirth, Guideline, HELLP, Placenta, Plasma, HELLP syndrome, Placentation, Medical device

QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.
  • The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor (“PLGF”) in maternal plasma specimens.
  • With the Triage PLGF test, clinicians can be positioned to better detect angiogenic imbalance and assess the risk for these complications.
  • The Triage PLGF test is available to customers in Canada for use with the Triage MeterPro instrument.

Richard F. Spaide, MD of the Vitreous Retina Macula Consultants of New York Awarded the Arnall Patz Medal by the Macula Society

Retrieved on: 
Tuesday, February 20, 2024
Research, MD, Consultant, Premature, Retinopathy, Annual general meeting, Arnall Patz, Book

NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Vitreous Retina Macula Consultants of New York ( VRMNY ), the largest retina vitreous center in the New York Metropolitan area, has announced that its esteemed ophthalmologist Richard F. Spaide, MD, was awarded the Arnall Patz Medal at The Macula Society 's 47th Annual Meeting on February 9th, 2024.

Key Points: 
  • NEW YORK, Feb. 20, 2024 /PRNewswire/ -- Vitreous Retina Macula Consultants of New York ( VRMNY ), the largest retina vitreous center in the New York Metropolitan area, has announced that its esteemed ophthalmologist Richard F. Spaide, MD, was awarded the Arnall Patz Medal at The Macula Society 's 47th Annual Meeting on February 9th, 2024.
  • Dr. Spaide was selected as the honoree of the Arnall Patz Medal by the awards committee of The Macula Society.
  • The Macula Society is the preeminent organization for specialists in the field of macula and retinal diseases.
  • The Arnall Patz Medal is awarded to those who have made outstanding contributions to the understanding of retinal vascular diseases in honor of ophthalmologist Arnall Patz, who is known for his landmark work on retinopathy of prematurity.

Sibel Announces its 4th FDA Clearance for Continuous Wearable Vital Signs Monitoring with ANNE® One and Additional Strategic Collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago

Retrieved on: 
Wednesday, February 7, 2024
Continuity, Research institute, Hospital, Research, Patient, Adolescence, Temperature, Lurie Children's Hospital, FDA, Vital signs, ECG, Entrepreneurship, Food, Health, Premature, Disability, Assistant, Neurology, Feinberg School of Medicine, Oxygen saturation (medicine), IZotope, Pleasure, Digital health, Nursing

CHICAGO, Feb. 7, 2024 /PRNewswire/ -- Sibel Health, a leading digital health company, announced today that its continuous wearable monitoring solution, ANNE® One, has received another 510(k) clearance from the U.S. Food and Drug Administration (FDA). The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements. In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.

Key Points: 
  • The ANNE® One platform now allows for continuous ambulatory ECG monitoring, SpO2, temperature, and non-invasive blood pressure measurements.
  • In addition, this new clearance extends the population to include individuals 12 years and above for monitoring in the home and hospital settings.
  • Steve Xu MD, Co-Founder and CEO of Sibel Health, said "Our mission here at Sibel Health is to deliver Better Health Data for All®.
  • Sibel Health also announces a new collaboration with Ann & Robert H. Lurie Children's Hospital of Chicago and its research enterprise, Stanley Manne Children's Research Institute.

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy

Retrieved on: 
Tuesday, January 9, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Development, Guggenheim Partners, BPD, Mother, Neonatology, Gestational age, Place of birth, License, Risk, Disease, Premature, Bronchopulmonary dysplasia, Pharmaceutical industry

OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of fetal growth and development, and its binding protein, IGFBP-3.

Key Points: 
  • OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of fetal growth and development, and its binding protein, IGFBP-3.
  • For the developing fetus, mothers are the primary source of IGF-1.
  • Clinical studies conducted to date have demonstrated OHB-607’s potential to significantly reduce the risk of severe BPD1.
  • Their deep expertise in neonatology will help to rapidly advance this promising therapy to patients.”
    Guggenheim Securities LLC acted as exclusive financial advisor to Oak Hill Bio and Goodwin Procter LLP served as its legal advisor.

MARCH OF DIMES WELCOMES HOUSE PASSAGE OF PREEMIE REAUTHORIZATION ACT AIMED AT PREVENTING PRETERM BIRTHS

Retrieved on: 
Thursday, December 14, 2023
Woman, Infant, Research, D-DE, Black in AI, Representative, Mortality, House, Mariannette Miller-Meeks, Senate, Premature, Preterm birth, PREEMIE Reauthorization Act, Plague, HHS, Death, Family, Louisiana House of Representatives, Report card, Legislation, Birth control, White, Jen Kiggans, Dime

ARLINGTON, Va., Dec. 14, 2023 /PRNewswire/ -- On the heels of March of Dimes' latest Report Card showing the U.S. preterm birth rate remains alarmingly high at 10.4%, the U.S. House of Representatives took a big step forward in addressing the crisis, unanimously approving the PREEMIE Reauthorization Act of 2023 (H.R. 3226) earlier this week. March of Dimes hailed the bipartisan vote that represents the government's commitment to prevent preterm birth and its consequences, the leading contributor to infant death.

Key Points: 
  • March of Dimes hailed the bipartisan vote that represents the government's commitment to prevent preterm birth and its consequences, the leading contributor to infant death.
  • "Every baby deserves a healthy start and reauthorizing the PREEMIE Act will help us toward that goal," Rep. Eshoo said following House passage.
  • "Since it was first passed in 2006, the PREEMIE Act has helped researchers and doctors identify the causes of premature births and work to prevent them.
  • March of Dimes, together with coalition partners, has successfully advocated for the bill's reauthorization every five years since its initial passage in 2006.

Public advisory - Unauthorized injectable drug products sold online by Canlab Research may pose serious health risks

Retrieved on: 
Wednesday, December 13, 2023
Sale, Peptide, Infant, Abdominal pain, Headache, Triptorelin, Patient, Oxytocin, Ovulation, Water intoxication, Pharyngitis, Infection, Oxygen, Background, Amniotic fluid, Erectile dysfunction, Lethargy, Pharmacy, Vomiting, Placenta, Osteoporosis, Safety, Fertility, Argyreia nervosa, Asphyxia, Canada Border Services Agency, DIN, Pelvimetry, Uterine rupture, Nursing, Drug identification number, Toxemia, Health, Diarrhea, Bleeding, Health Canada, Nausea, Chronic pain, Plasma protein binding, Fetus, Allergy, Somnolence, Anaphylaxis, Endometriosis, Depression, Hormone, Risk, Constipation, History, Premature, Long QT syndrome, Stroke, Seizure, Pain, Natural product, Drug, Upper respiratory tract infection, NPN, Prostate cancer, Prescription drug, Pituitary gland, Dietary supplement

Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.

Key Points: 
  • Health Canada is warning consumers not to buy unauthorized injectable drug products from Canlab Research because they may pose serious health risks.
  • The products are promoted as peptides and are sold online via Canlab Research websites including www.canlabresearch.com and www.canlab.net .
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • This is not a complete description of all the unauthorized health products advertised and sold on the Canlab Research websites.

SERA PROGNOSTICS ANNOUNCES PRIMARY ENDPOINT CRITERIA MET IN PIVOTAL PRIME STUDY INTERIM LOOK - ENROLLMENT TO STOP DUE TO SUCCESS

Retrieved on: 
Wednesday, December 6, 2023
Premature, Health, Patient, AVERT, DSMB, Mother, Data monitoring committee, Dietary supplement, Pharmaceutical industry

The Company has adopted the DSMB's recommendation and will stop PRIME study enrollment to focus on analyzing and reporting the available data.

Key Points: 
  • The Company has adopted the DSMB's recommendation and will stop PRIME study enrollment to focus on analyzing and reporting the available data.
  • "We are excited by this report of efficacy from the DSMB," said Zhenya Lindgardt, President and CEO of Sera Prognostics.
  • "It is unexpected for trials to stop early for efficacy since most statistical power is typically reserved for the final analysis, which makes this event that much more encouraging.
  • We look forward to sharing top-line results once we have had a chance to analyze the interim look data.

Prolacta's Human Milk-Based Nutrition Has Touched the Lives of 100,000 Premature and Critically Ill Infants Globally

Retrieved on: 
Friday, November 17, 2023
Hospice and palliative medicine, Necrotizing enterocolitis, Disease, Premature, NICU, Pediatrics, Medical Center, BPD, Prenatal care, Neonatology, Mortality, ROP, Monica E. Peek, Place of birth, Retinopathy, Division, Health, Bronchopulmonary dysplasia, Exclusive, MD, Mother, Death, Extrapyramidal system, Hospital, Singing, NEC, Dietary supplement, Nursing, Birth control

DUARTE, Calif., Nov. 17, 2023 /PRNewswire/ -- Prolacta Bioscience, the world's leading hospital provider of 100% human milk-based nutritional products for critically ill, premature infants, proudly commemorates Prematurity Awareness Month 2023 by announcing a significant milestone: more than 100,000 preterm and critically ill infants' lives have been touched by Prolacta's Exclusive Human Milk Diet (EHMD) in hospitals worldwide.1

Key Points: 
  • "We're proud that for more than two decades, Prolacta's 100% human milk-based nutritional products have supported hospitals on the forefront of progressive care to help so many fragile infants in need."
  • The Peeks advocated for Leah Michelle to be on an EHMD and asked the hospital to fortify Brandi's breast milk with a Prolacta fortifier.
  • All types of hospitals have seen the benefits of an EHMD to treat the critically ill, premature infants in their care, including those supporting underserved populations.
  • One example is Los Angeles General Medical Center (formerly LAC+USC Medical Center), among the largest public hospitals in the U.S.